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Research
The weight of evidence supports an association 
between early-life exposure to lead and impaired 
cognitive function in children (Bellinger 2004; 
Lanphear et al. 2005; Needleman 2004). Even 
at low levels, childhood lead exposure results 
in cognitive dysfunction that persists into 
adulthood (Mazumdar et al. 2011). In older 
adults, chronic environmental exposure to lead 
is associated with accelerated cognitive decline 
(van Wijngaarden et al. 2009; Weisskopf 
et al. 2004, 2007; Weuve et al. 2009; Wright 
et al. 2003). Whether early exposure to lead 
has latent effects that contribute to neuro-
degenerative disease in old age is unknown.
Barker and Osmond (1986) demonstrated 
an inverse relationship between birth weight 
and the incidence of cardiovascular disease. 
The Barker hypothesis, also known as the fetal 
basis of adult disease (FeBAD) hypothesis, 
states that many adult diseases have a fetal 
origin (Barker 1995). According to FeBAD, 
injury occurring at a critical period of develop-
ment could result in changes in gene expres-
sion or gene imprinting, leading to deficits 
that become apparent later in life.
Alzheimer’s disease (AD) is a progressive, 
neurodegenerative disorder that results in 
dementia and death. The two classical lesions 
of AD are a) neuritic plaques containing 
extracellular deposits of the amyloid β (Aβ) 
proteins and b) neurofibrillary tangles, which 
are bundles of paired, helically wound fila-
ments inside neurons (Selkoe 2008). The lead-
ing hypothesis for AD pathogenesis suggests 
that accumulation of Aβ in the brain is the 
primary influence driving its development 
(Hardy and Selkoe 2002). Animal and cell 
culture studies have shown that lead exposure 
affects Aβ production (Gu et al. 2011; Huang 
et al. 2011).
Recent animal studies suggest the expres-
sion of AD-related genes is altered in rodents 
and primates exposed to lead as infants. 
Basha et al. (2005) exposed newborn rats to 
lead; at 20 months of age, the gene encoding 
β-amyloid precursor protein (APP) exhib-
ited a delayed overexpression (Basha et al. 
2005). The increase in APP gene expression 
in old age was accompanied by an elevation 
in Aβ in brain tissue. These changes were not 
seen in rats exposed to lead as adults, sug-
gesting that early timing of lead exposure is 
an important determinant of gene expression 
and protein production. The same group also 
found that cynomolgus monkeys exposed to 
lead as infants had more neuritic plaques in 
their brains and exhibited higher levels of 
APP and Aβ than did monkeys not exposed 
to lead (Wu et al. 2008). In humans, case 
studies have reported that children who died 
of acute lead poisoning had neurofibrillary 
tangles in their brains at autopsy (Hess and 
Straub 1974; Niklowitz 1975; Wisniewski 
et al. 1979).
The long latent period between exposure 
and outcome poses unique challenges to the 
study of the FeBAD hypothesis. Most previ-
ous research on early-life environmental influ-
ences on neurodegenerative diseases has been 
cross-sectional or retrospective in design, thus 
limited in its ability to collect data on early 
exposures. Use of an existing cohort with 
banked data, ideally with biological samples, 
is a promising method for studying whether 
early-life environmental exposures result in 
neurodegeneration.
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Ba c k g r o u n d: Animal studies suggest that early-life lead exposure influences gene expression and 
production of proteins associated with Alzheimer’s disease (AD).
oBjectives: We attempted to assess the relationship between early-life lead exposure and potential 
biomarkers for AD among young men and women. We also attempted to assess whether early-life 
lead exposure was associated with changes in expression of AD-related genes.
Me t h o d s : We used sandwich enzyme-linked immunosorbent assays (ELISA) to measure plasma 
concentrations of amyloid β proteins Aβ40 and Aβ42 among 55 adults who had participated as 
newborns and young children in a prospective cohort study of the effects of lead exposure on 
development. We used RNA microarray techniques to analyze gene expression.
re s u l t s: Mean plasma Aβ42 concentrations were lower among 13 participants with high umbili-
cal cord blood lead concentrations (≥ 10 μg/dL) than in 42 participants with lower cord blood 
lead concentrations (p = 0.08). Among 10 participants with high prenatal lead exposure, we found 
evidence of an inverse relationship between umbilical cord lead concentration and expression of 
ADAM metallo  peptidase domain 9 (ADAM9), reticulon 4 (RTN4), and low-density lipoprotein 
receptor-related protein associated protein 1 (LRPAP1) genes, whose products are believed to affect 
Aβ production and deposition. Gene network analysis suggested enrichment in gene sets involved in 
nerve growth and general cell development.
co n c l u s i o n s: Data from our exploratory study suggest that prenatal lead exposure may influence 
Aβ-related biological pathways that have been implicated in AD onset. Gene network analysis iden-
tified further candidates to study the mechanisms of developmental lead neurotoxicity.
key w o r d s : Alzheimer’s disease, children, fetal basis of adult disease, human, lead. Environ Health 
Perspect 120:702–707 (2012).  http://dx.doi.org/10.1289/ehp.1104474 [Online 7 February 2012]Prenatal lead, adult Aβ levels, and gene expression
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The Boston prospective study was one of 
several cross-sectional and cohort studies ini-
tiated in the late 1970s and early 1980s to 
study the relationship between lead and early 
development. Follow-up of the Boston cohort 
showed that the association noted between 
blood lead concentration and IQ at 2 years 
of age continued at 10 years of age (Bellinger 
et al. 1991). A recent report suggests that the 
association between early-life lead exposure 
and cognitive function persists into adulthood 
(Mazumdar et al. 2011).
The objective of this exploratory study was 
to assess the relationship between early-life envi-
ronmental lead exposure and potential biomark-
ers for AD among a group of young adults who 
were enrolled in the Boston prospective cohort 
study as newborns. We also attempted to assess 
whether developmental exposure to lead was 
associated with changes in expression of genes 
believed to be involved in AD pathogenesis.
Materials and Methods
Study population. Between August 1979 and 
April 1981, a cohort of 249 infants was estab-
lished among babies born at the Brigham and 
Women’s Hospital in Boston, Massachusetts. 
Umbilical cord blood lead concentrations were 
measured, and postnatal blood lead concentra-
tions and develop  ment were assessed at 6, 12, 
18, 24, and 57 months, and again at 10 years. 
Follow-up of this cohort at 10 years of age 
included 148 children (87.6% of those con-
sidered eligible; 59.4% of the original cohort) 
(Bellinger et al. 1992).
In January 2009, members of the origi-
nal cohort were mailed an introductory letter 
explaining a new study regarding early-life 
lead exposure and health outcomes in adult-
hood. Names and last known addresses were 
available for only the 148 participants who 
took part in the 10-year follow-up study. 
The Committee for Clinical Investigation 
at Children’s Hospital Boston approved the 
study, and each participant provided written 
informed consent.
Measures of exposure, birth to 10 years. 
Blood samples were obtained from umbilical 
cords at birth, from participants using capillary 
tubes at ages 6, 12, 18, and 24 months, and via 
venipuncture at 57 months and 10 years. Blood 
lead concentrations were measured in dupli-
cate using graphic furnace atomic absorption 
  spectrometry (Bellinger et al. 1987, 1992).
Measurement of covariates. At the time 
of enrollment in the present study, partici-
pants completed a questionnaire that gath-
ered information on demographics, medical 
history, family medical history, concurrent 
medications, and alcohol and tobacco use. 
Information about other potentially impor-
tant variables, including maternal medication 
and alcohol and tobacco use, was available in 
records from earlier assessments.
Plasma Aβ subspecies isolation. Blood 
used for plasma Aβ analysis was collected from 
the present cohort via venipuncture in EDTA 
tubes, processed immediately (centrifuged 
and aliquotted as plasma, buffy coat, and red 
blood cells), and then stored at –80°C. Plasma 
samples were sent to and analyzed in the 
Selkoe Laboratory at Brigham and Women’s 
Hospital.
Aβ40 and Aβ42 were assayed by sandwich 
enzyme-linked immunosorbent assays. Plates 
were coated with capture antibodies (2G3 
for Aβ40 and 21F12 for Aβ42) in phosphate-
buffered saline (PBS), incubated for 4 hr at 
room temperature, and then blocked with 
4% Block Ace (BA; AbD Serotec, Raleigh, 
NC) at 4°C. Plates were washed three times 
with PBS containing Tween 20, and samples 
were freshly diluted in 0.4% BA, loaded into 
the wells, and incubated with antibodies for 
2 hr at room temperature. Samples were then 
reincubated in solution containing detec-
tor biotinylated antibody (266B) for 2 hr 
at room temperature. Finally, samples were 
incubated with strept  avidin alkaline phos-
phatase (Promega, Madison, WI) in PBS for 
1 hr at room temperature and washed three 
times with Tris-buffered saline. After adding 
AttoPhos (Promega), the signal was amplified 
and measured with a Victor2 microtiter plate 
reader (PerkinElmer, Boston, MA).
RNA preparation. Blood used for RNA 
microarray analysis was collected from the 
present cohort via venipuncture into PAXgene 
tubes (QIAGEN Inc., Valencia, CA). Blood 
tubes were stored at –80°C until RNA extrac-
tion. Total RNA was isolated according to 
manufacturer protocols and purified using 
the PAXgene Blood RNA kit (QIAGEN 
Inc.). RNA extraction was performed at the 
General Clinical Research Center (GCRC) 
laboratories at Children’s Hospital Boston for 
the initial 12 samples. The GCRC laboratory 
closed during the study, and RNA extraction 
was performed on the remaining 37 samples 
at the Molecular Genetics Core Facility of 
the Children’s Hospital Boston Intellectual 
and Developmental Disabilities Research 
Center (IDDRC).
Microarray hybridization. Gene tran-
script expression was analyzed using Affymetrix 
Human Genome 1.0 ST array (Affymetrix, 
Santa Clara, CA). All RNA samples were ana-
lyzed at the Microarray Core Facility of the 
Dana-Farber Cancer Institute. Array data were 
retrieved and processed using the BioConductor 
framework, version 2.9 (Gentleman et al. 2004; 
http://www.bioconductor.org/), and tested for 
quality using the arrayQualityMetrics package 
(Kauffmann et al. 2009).
Statistical analysis. Statistical methods 
focused on estimating the association between 
early-life blood lead concentrations and plasma 
Aβ subspecies concentrations. We calculated 
correlation coefficients and fitted linear regres-
sion models with individual Aβ sub  species 
as the response and lead concentrations as 
the predictors. We fitted separate models for 
each measurement of lead concentration, and 
the average lead concentrations over the first 
10 years of life were modeled as simple con-
tinuous variables and as log-transformed vari-
ables to account for heteroskedasticity and 
a possible nonlinear relationship between 
lead exposure and plasma Aβ subspecies. 
Outcomes were plasma Aβ42 concentration, 
Aβ40 concentration, and the ratio of Aβ42 and 
Aβ40 concentrations, which also were modeled 
before and after log transformation. We also 
stratified analyses by high and low prenatal 
lead levels, where high lead level was defined 
as > 10 μg/dL. We chose 10 μg/dL as our cut-
off because this definition for high lead level 
was used in the original cohort study and was 
part of the initial sampling and recruitment 
strategy (Bellinger et al. 1987).
Microarray data analysis. RNA expression 
data from 49 samples were evaluated using 
standard quality control criteria to assess the 
variability across samples, for example, batch 
effects that may have resulted from experi-
ments being performed on different days or 
by different individuals, as well as the spatial 
distribution of probe intensities across chips. 
Arrays were then background corrected and 
normalized with robust multichip analysis. 
IsoGene (Lin et al. 2007), an R statistical soft-
ware package (http://www.r-project.org/), was 
used to identify genes with significant changes 
of gene expression levels in response to an 
increase in cord blood lead concentration at 
a 5% false discovery rate (FDR; determined 
using the Benjamini–Hochberg correction for 
multiple testing). A total of 245 probes map-
ping to 196 unique genes were considered 
significant using this criteria. To identify the 
subset of genes exhibiting monotonous changes 
in expression levels with increasing prenatal 
lead levels (at |r| ≥ 0.9), the 10 samples with 
blood prenatal blood levels > 10 μg/dL were 
binned into groups so that each group had 
approximately the same number of samples 
(lead exposures levels 10–12, 12–15, 15–18, 
18–20 μg/dL) and analyzed in GATE (Grid 
Analysis of Time Series Expression) software 
(MacArthur et al. 2010; http://amp.pharm.
mssm.edu/maayan-lab/gate.htm). Genes iden-
tified in the IsoGene analysis that passed the 
|r| ≥ 0.9 correlation filter were subsequently 
tested for Gene Ontology enrichment using 
the GeneMANIA Cytoscape plugin (Warde-
Farley et al. 2010; http://www.genemania.org/
plugin/). GeneMANIA extends a provided 
gene list with functionally similar and interact-
ing genes to generate a functional association 
network. Association data include protein and 
genetic interactions, pathways, coexpression, 
colocalization, and protein domain similarity. Mazumdar et al.
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In addition, we reviewed the literature to 
determine if any of the identified genes were 
reported to be implicated in AD biology.
Results
We located 89 (60%) of the 148 cohort mem-
bers who participated in the 10-year follow-up 
study. Of these, 58 enrolled in the present 
study. Fifty-five blood samples were available for 
plasma studies. The study population generally 
consisted of white,   college-educated children 
with college-educated mothers. Participants 
were similar to members of the original cohort 
in terms of demographic factors, measures of 
socioeconomic status, blood lead history, and 
IQ scores in early childhood (Table 1).
Blood lead concentration. Mean blood 
lead concentration in the 55 cohort members 
for whom plasma samples were available was 
lowest at 10 years of age (3.0 μg/dL) and high-
est at 12 months of age (9.8 μg/dL; Table 1). 
Median concentrations followed a similar 
pattern, except median blood lead concentra-
tion was highest at 2 years of age [8.1 μg/dL; 
see Supplemental Material, Figure 1 (http://
dx.doi.org/10.1289/ehp.1104474)]. The high-
est lead concentrations were seen in infancy 
and early childhood, possibly reflecting greater 
lead intake through hand-to-mouth activity 
and higher exposures in that era.
Aβ analysis. Scatterplots of prenatal lead 
concentration, Aβ42 concentration, and 
Aβ42:Aβ40 ratio suggest an inverse relationship 
between prenatal blood lead concentration and 
plasma Aβ subspecies in adulthood (Figure 1). 
The mean ± SD Aβ42 concentration among 
participants with prenatal lead exposure 
< 10 μg/dL was 36.6 ± 43.1 pM, compared 
with 22.8 ± 14.7 pM among participants 
with higher prenatal lead exposure (p = 0.08; 
Figure 1). The Aβ42:Aβ40 ratio showed a 
similar pattern between the two groups, 
with a ratio of 0.40 ± 0.30 for participants 
with prenatal lead concentration ≥ 10 μg/dL 
and 0.32 ± 0.17 for participants with prena-
tal blood lead levels < 10 μg/dL (p = 0.27). 
Models of untransformed and log-transformed 
lead concentrations at different time points 
did not indicate clear or consistent associa-
tions with plasma Aβ42 or the Aβ42:Aβ40 
ratio. Visual inspection of the scatterplots 
among participants with high prenatal lead 
exposure reveals an apparent inverse relation-
ship between umbilical cord lead concentra-
tion and plasma Aβ42 concentration as well as 
plasma Aβ42:Aβ40 ratio (Figure 1).
AD-related gene expression. Forty-nine 
samples were available for RNA analysis, and 
36 samples that met standard quality control 
Table 1. Characteristics of the participants at 28–30 years of age and comparison with non  participants.
Characteristic
Participants
Nonparticipants 
(n = 90)
With plasma 
available (n = 55)
With RNA used in 
analysis (n = 36)
Participants
Age at testing (years) 28.9 ± 0.5 29.0 ± 0.4 —
Body mass index (kg/m2) 25.2 ± 4.5 25.0 ± 4.7
College graduate 83.6 91.7 —
Currently smoke 18.2 19.4 —
Alcohol use > 2 drinks/week 38.1 33.3 —
Mother or father with dementia 3.4 0 —
Currently taking oral contraceptives 14.5 22.2 —
Currently taking medicine other than oral contraceptives 0 0 —
Male 47.2 36.8 53.3
White 94.5 94.7 94.4
Weeks of gestation 40.0 ± 1.9 39.8 ± 2.3 40.0 ± 1.6
Birth weight (kg) 3.4 ± 0.5 3.4 ± 0.5 3.4 ± 0.5
Blood lead concentration (μg/dL)
Cord 6.3 ± 5.0 6.3 ± 5.4 7.9 ± 5.4
6 months 7.8 ± 5.1 7.4 ± 5.6 9.3 ± 8.0
12 months 9.8 ± 6.8 9.6 ± 7.0 9.9 ± 6.4
24 months 8.1 ± 4.3 7.7 ± 4.0 8.8 ± 5.1
4 years 6.6 ± 3.4 6.4 ± 3.9 6.1 ± 4.0
10 years 3.0 ± 2.5 2.5 ± 2.3 2.9 ± 2.4
IQ at 4 years of age  118.4 ± 14.0 117.3 ± 14.4 114.3 ± 15.4
IQ at 10 years of age  118.7 ± 14.2 116.1 ± 16.3 114.5 ± 13.8
Participants’ mothers
Age at delivery (years) 30.6 ± 4.0 31.4 ± 4.0 30.4 ± 4.2
College graduate 60.0 72.2 62.2
Maternal IQ 124.5 ± 17.8 127.6 ± 14.1 124.9 ± 14.7
Tobacco use during pregnancy 23.6 33.3 22.5
Alcohol use during pregnancy 47.2 48.4 42.7
Data are percent yes or mean ± SD.
Figure 1. Scatterplots of prenatal (umbilical cord) lead concentrations versus plasma Aβ subspecies concentrations (n = 55 plasma samples). Aβ42 (A) and 
Aβ40 (B) at 28 years of age and Aβ42:Aβ40 ratio at 29 years of age (C).
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criteria were included in analyses. All of the 
36 samples used in the analyses were processed 
at the IDDRC. The expression of 196 genes 
was significantly associated (5% FDR) with 
increasing cord blood lead level. Because of 
the small sample size, an additional filter was 
applied, retaining only genes with a corre-
lation of |r| ≥ 0.9 with an increasing (or 
decreasing) trend between cord blood levels of 
10–20 μg/dL. The 39 retained genes [listed in 
Supplemental Material, Table 1 (http://dx.doi.
org/10.1289/ehp.1104474)] exhibited a much 
higher level of variation in gene expression 
in relation to cord blood level concentrations 
< 10 μg/dL (n = 28) compared with concen-
trations > 10 μg/dL (n = 10; data not shown).
Three of the 39 identified genes encode 
proteins that have been reported to affect 
Aβ production and deposition in the brain; 
ADAM metallopeptidase domain 9 (ADAM9), 
low-density lipoprotein receptor-related protein 
associated protein 1 (LRPAP1) and reticulon 
4 (RTN4). Figure 2 shows normalized probe 
intensities (measures of relative gene expression) 
of these genes in relation to prenatal blood lead 
concentrations for individual participants.
Genes whose expression showed an 
increasing or decreasing trend in relation 
to prenatal lead level were found to interact 
directly or indirectly in physical interaction 
and coexpression networks [see Supplemental 
Material, Figure 2 (http://dx.doi.org/10.1289/
ehp.1104474)]. Although the network analy-
sis did not exhibit a direct involvement with 
amyloid pathways, it identified enrichment of 
genes associated with the (negative) regulation 
of neurogenesis, nerve growth, and general cell 
development (Table 2).
Discussion
Two observations from this study support the 
hypothesis that early-life (prenatal) lead expo-
sure influences the biological pathways believed 
to be involved in AD. First, participants with 
higher prenatal lead exposure (umbilical cord 
lead concentration > 10 μg/dL) had lower 
mean plasma Aβ42 concentrations than did 
participants with low and moderate prenatal 
lead levels. Data from participants with higher 
prenatal lead levels showed an apparent inverse 
relationship between umbilical cord lead con-
centration and both plasma Aβ42 concentra-
tion and plasma Aβ42:Aβ40 ratios.
The second finding is that among the 
10 participants with higher prenatal lead 
exposure (> 10 μg/dL), there were inverse rela-
tionships between umbilical cord lead concen-
trations and expression of ADAM9, RTN4, and 
LRPAP1, genes whose products are believed to 
affect Aβ production and deposition in the 
brain (Allinson et al. 2003; Cong and Jia 2011; 
He et al. 2004; Hyman et al. 2000; Murayama 
et al. 2006). The expression of 39 genes 
appeared to be associated with prenatal blood 
lead levels within this subgroup, but these three 
genes have been previously found relevant to 
AD pathogenesis.
The product of ADAM9 is a member of 
the ADAM (a disintegrin and metallopro-
tease domain) family. Members of this family 
are membrane-anchored proteins that have 
been implicated in a variety of biological pro-
cesses, including neurogenesis. The product 
of ADAM9 is believed to act as an α-secretase 
and cause non  amyloidogenic cleavage of APP 
(Allinson et al. 2003; Cong and Jia 2011; 
Deuss et al. 2008).
The product of RTN4 is a potent neurite 
outgrowth inhibitor that may also help block 
the regeneration of the central nervous system 
in higher vertebrates. RTN4 is also implicated 
in the amyloid cascade. Animal studies have 
Figure 2. Gene expression levels for selected AD-related genes: normalized probe intensities for 
ADAM9 (A), RTN4 (B), and LRPAP1 (C) at 29 years of age in relation to prenatal (umbilical cord) blood lead 
concentrations. Data points from samples with cord blood lead level concentrations < 10 μg/dL (n = 26) 
were not used to identify genes whose expression was significantly associated with blood lead levels 
> 10 μg/dL (n = 10) and are plotted for reference only.
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Table 2. Network analysis representing functional association of 39 genes with altered expression at 
prenatal lead levels > 10 μg/dL.
Gene Ontology biological process Q-value Count [annotated (overall)]
Neuron development    
Negative regulation of axonogenesis 0.00080 4 (13)
Negative regulation of cell projection organization 0.00328 4 (21)
Negative regulation of neurogenesis 0.00634 4 (27)
Nerve growth factor receptor signaling pathway 0.00990 7 (215)
Regulation of axonogenesis 0.00990 4 (34)
Regulation of neuron projection development 0.08320 4 (63)
Cell development  
Negative regulation of cell development 0.01040 4 (36)
Negative regulation of cell differentiation 0.10500 5 (148)
Immune response  
Response to abiotic stimulus 0.08320 6 (218)
T-cell receptor signaling pathway 0.08490 4 (67)
Data are Gene Ontology categories (http://www.geneontology.org/) and Q-values (minimum FDR at which the test is 
considered significant) from an FDR-corrected hypergeometric test for enrichment. Q-Values were estimated using the 
Benjamini–Hochberg procedure. Counts reflect genes with this annotation in the query set (39 genes of interest identi-
fied by differential monotonous change of expression in response to lead exposure) compared with the overall number 
of genes in the GeneMANIA background set with this annotation and at least one interaction (numbers in parentheses).Mazumdar et al.
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suggested that the product of RTN4 decreases 
cleavage of APP to its amyloidogenic products 
(He et al. 2004; Murayama et al. 2006).
Low-density lipoprotein receptor-related 
protein (LRP) is thought to play an important 
role in determining the balance between Aβ 
synthesis and clearance mechanisms (Hyman 
et al. 2000). The product of the LRPAP1 gene 
blocks ligand-binding sites of LRP and inter-
feres with Aβ clearance. In accordance with 
its role in the amyloidogenic pathway, varia-
tion in LRPAP1 has been associated with the 
risk of developing AD (Sanchez et al. 2001).
Although gene network analysis did 
not suggest a direct involvement with amy-
loid pathways, several genes that exhibited 
decreased expression in relation to prenatal 
lead concentration are involved in the (nega-
tive) regulation of neurogenesis, nerve growth, 
and general cell development. This provides 
additional support to the hypothesis that 
developmental exposure to lead can cause 
changes in expression for genes important in 
neurological development and disease. Our 
findings were similar to those seen in zebrafish 
embryos (Peterson et al. 2011) after research-
ers exposed them to a sublethal dose of lead 
and analyzed global transcriptional alterations.
The known association between AD and 
both limited education and occupational 
attainment (Cobb et al. 1995; Snowdon et al. 
2000; Stern et al. 1994), often referred to as 
the cognitive reserve hypothesis, suggests that 
risk factors for AD may be established early in 
life. The cognitive reserve hypothesis posits that 
higher levels of education, or other measures of 
cognitive ability early in life, provide protec-
tion against cognitive decline, suggesting that 
early education leads to the development of 
efficient and/or flexible neural networks more 
capable of coping with the disruption imposed 
by brain pathology (Stern 2009). An alterna-
tive explanation is that the same environmen-
tal influences that result in poor cognition in 
childhood and early adulthood have persis-
tent and/or latent effects that contribute to the 
development of dementia during old age.
Our study used prospectively collected 
lead exposure information from a cohort study 
started > 30 years ago. The long latent period 
between exposure and outcome poses signifi-
cant challenges to the study of the FeBAD 
hypothesis, and the imprecision of exposure 
classification based on ecological data or recall 
is one of the biggest criticisms of this work 
(Joseph and Kramer 1996). Our study mini-
mized the uncertainty around exposure assess-
ment by using samples that were collected 
and analyzed in real time.
Our study has a number of limitations, 
the most important of which is a small num-
ber of participants. Specifically, we had only 
13 participants with prenatal blood lead levels 
> 10 μg/dL (including 10 with gene expression 
data), which turned out to be the exposure 
level of greatest interest. The Boston cohort 
was specifically assembled to investigate the 
cognitive effects of what was then considered 
to be low-level lead exposure. Repeating this 
analysis among participants from cohorts with 
higher prenatal lead levels may provide more 
data around the exposure levels of interest, 
therefore providing more power and more 
precise estimates of association.
Another important limitation is the use 
of plasma measurements of Aβ instead of 
cerebro  spinal fluid measurements or neuro-
pathological changes (as would be seen at 
autopsy) to define the outcome. The published 
data on plasma Aβ levels in AD are contra-
dictory, with plasma Aβ levels reported to 
be higher (Kosaka et al. 1997; Sobow et al. 
2005), lower (Buerger et al. 2009; Cosentino 
et al. 2010), or unchanged (Abdullah et al. 
2007; Fukumoto et al. 2003; Giedraitis et al. 
2007; Tamaoka et al. 1996) in cases with 
AD compared with controls. A recent meta-
  analysis found that in cross-sectional studies, 
AD patients in their 60s and 70s had lower 
Aβ42 plasma concentrations compared with 
cognitively normal individuals (Song et al. 
2011), although this pattern was not seen in 
longitudinal studies. A proposed mechanism 
for the discrepancy between high Aβ levels 
seen in the brains of AD cases and low Aβ 
subspecies levels in plasma is that there is com-
partmentalization of Aβ peptides in the brain 
among patients with AD (Schupf et al. 2008). 
There are no reports regarding the association 
between plasma Aβ among young adults and 
the development of AD.
An additional limitation of our study is 
that we did not measure blood lead levels at 
the same time that we measured plasma Aβ 
and gene expression levels. In a recent pooled 
analysis, current blood lead levels and aver-
age lifetime estimates were stronger predic-
tors of intellectual deficits in late childhood 
than was early childhood lead concentration 
(Lanphear et al. 2005). In older adults, how-
ever, recent studies found that current blood 
lead levels were not associated with cognitive 
function in adults, suggesting that early-life 
or accumulated exposures may be etiologi-
cally more important (van Wijngaarden et al. 
2011). Future studies would be strengthened 
if associations are estimated between outcome 
and current blood lead levels, as well as early 
blood lead levels.
An additional concern is the use of mul-
tiple testing in microarray experiments. Given 
thousands of genes, it is possible that the 
ones we found to be associated with prenatal 
lead exposure were so associated by chance 
(Ioannidis 2005). We corrected for this limi-
tation by looking at genes with continuous 
changes at higher prenatal levels (following 
the trend seen in scatterplots) and also by 
comparing these with genes implicated in AD 
pathogenesis. However, our findings should 
be considered preliminary.
If early-life lead exposure influences bio-
logical processes involved in AD pathogenesis, 
the implications for public health practice are 
substantial. Lead exposure in the United States 
reached its peak in the 1970s, and the children 
exposed at that time, now adults, may be at 
increased risk for neurodegenerative disease. If 
similar results are achieved in a larger cohort, 
our study could provide support for screen-
ing strategies that identify adults who may 
be at higher risk for neurodegenerative dis-
ease because of childhood exposures, as well as 
identify an opportunity for disease prevention.
Conclusions
Data from our study suggest that early-life lead 
exposure may influence the biological path-
ways that have been implicated in AD in old 
age. Gene network analysis identified further 
candidates for the study of the mechanisms of 
developmental lead neurotoxicity in humans.
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